Huabo Biopharm Co., Ltd.
14
3
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Role: lead
A Phase 2 Study of HB0017 in Psoriasis Patients
Role: lead
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Role: lead
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Role: lead
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Role: lead
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
Role: lead
A Study of HB0030 Injection in Patients With Advanced Solid Tumors
Role: lead
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Role: lead
A Study of Injection HB0025 in Patients With Advanced Solid Tumors
Role: lead
A Study of of HOT1030 in Patients With Advanced Solid Tumors
Role: lead
A Study of Injection HB0017 in Adult Healthy Volunteers
Role: lead
A Study of Injection HB002.1T in Subjects With Solid Tumor
Role: lead
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
Role: lead
A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration
Role: lead
All 14 trials loaded